Cargando…
578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therap...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777222/ http://dx.doi.org/10.1093/ofid/ofaa439.772 |
_version_ | 1783630852170711040 |
---|---|
author | Tran, Nikki Eschenauer, Gregory Scappaticci, Gianni Frame, David Miceli, Marisa H Patel, Twisha S |
author_facet | Tran, Nikki Eschenauer, Gregory Scappaticci, Gianni Frame, David Miceli, Marisa H Patel, Twisha S |
author_sort | Tran, Nikki |
collection | PubMed |
description | BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therapy is warranted. METHODS: We retrospectively reviewed and analyzed infectious complications for 6 months following CAR-T therapy infusion (CTI) in 39 adult and pediatric patients with R/R acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) at Michigan Medicine. RESULTS: Overall, 20 infections were identified in 16 of 39 patients (41%) following CTI [detailed in Table 1]; 8 (40%) infections occurred in the early period (Day 0–30) and 12 (60%) infections occurred during late period (Day 31–180). The most common infections were viral (n=10, 50%; 80% of viral infections were respiratory viruses), followed by 8 bacterial infections (40%), and 2 fungal infections (10%). More bacterial infections were seen in the early period post-CTI (30% vs. 10%, p = 0.019), whereas viral infections were more common during the late period (40% vs. 10%, p = 0.68). Antimicrobial prophylaxis prior to CTI and following CTI were similar (Table 2). The majority of patients included in the study had NHL (n=32, 82%). Mean age of the cohort was 52 ± 22 years, and 64% were male. 85% of the population developed cytokine release syndrome (CRS) with 67% grade 1–2 and 18% grade 3–5. As shown in Table 2, most baseline characteristics were similar between patients with and without infections post CTI except infected patients were older (63.3 ± 11.3 vs. 44.8 ± 24.2, p = 0.01) and more received steroids for CRS (56% vs 17%, p = 0.02). All-cause mortality within 6 months following CTI was similar in infected and uninfected groups (38% vs 26%, p= 0.50). Table 1 [Image: see text] Table 2 [Image: see text] CONCLUSION: Infectious complications are common following CAR-T therapy. We found the majority of infections to be caused by various bacteria or respiratory viruses in a cohort of patients with lymphoma as the most common underlying malignancy. DISCLOSURES: Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member) |
format | Online Article Text |
id | pubmed-7777222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77772222021-01-07 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy Tran, Nikki Eschenauer, Gregory Scappaticci, Gianni Frame, David Miceli, Marisa H Patel, Twisha S Open Forum Infect Dis Poster Abstracts BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therapy is warranted. METHODS: We retrospectively reviewed and analyzed infectious complications for 6 months following CAR-T therapy infusion (CTI) in 39 adult and pediatric patients with R/R acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) at Michigan Medicine. RESULTS: Overall, 20 infections were identified in 16 of 39 patients (41%) following CTI [detailed in Table 1]; 8 (40%) infections occurred in the early period (Day 0–30) and 12 (60%) infections occurred during late period (Day 31–180). The most common infections were viral (n=10, 50%; 80% of viral infections were respiratory viruses), followed by 8 bacterial infections (40%), and 2 fungal infections (10%). More bacterial infections were seen in the early period post-CTI (30% vs. 10%, p = 0.019), whereas viral infections were more common during the late period (40% vs. 10%, p = 0.68). Antimicrobial prophylaxis prior to CTI and following CTI were similar (Table 2). The majority of patients included in the study had NHL (n=32, 82%). Mean age of the cohort was 52 ± 22 years, and 64% were male. 85% of the population developed cytokine release syndrome (CRS) with 67% grade 1–2 and 18% grade 3–5. As shown in Table 2, most baseline characteristics were similar between patients with and without infections post CTI except infected patients were older (63.3 ± 11.3 vs. 44.8 ± 24.2, p = 0.01) and more received steroids for CRS (56% vs 17%, p = 0.02). All-cause mortality within 6 months following CTI was similar in infected and uninfected groups (38% vs 26%, p= 0.50). Table 1 [Image: see text] Table 2 [Image: see text] CONCLUSION: Infectious complications are common following CAR-T therapy. We found the majority of infections to be caused by various bacteria or respiratory viruses in a cohort of patients with lymphoma as the most common underlying malignancy. DISCLOSURES: Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member) Oxford University Press 2020-12-31 /pmc/articles/PMC7777222/ http://dx.doi.org/10.1093/ofid/ofaa439.772 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Tran, Nikki Eschenauer, Gregory Scappaticci, Gianni Frame, David Miceli, Marisa H Patel, Twisha S 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title | 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title_full | 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title_fullStr | 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title_full_unstemmed | 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title_short | 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy |
title_sort | 578. infections in patients treated with chimeric antigen receptor t-cells (car-t) therapy |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777222/ http://dx.doi.org/10.1093/ofid/ofaa439.772 |
work_keys_str_mv | AT trannikki 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy AT eschenauergregory 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy AT scappaticcigianni 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy AT framedavid 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy AT micelimarisah 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy AT pateltwishas 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy |